We conducted a retrospective cohort study of HIV-infected pregnant women and their infants enrolled in the DREAM programme for prevention of HIV mother-to-child transmission (MTCT) in Mozambique. All women delivering between May 2002 and December 2005 were offered participation. The programme consisted of the provision of highly active anti-retroviral therapy (HAART) to pregnant women until 6 months postpartum, and formula, clean water, nutritional supplementation, and continuing HAART to mothers if necessary.
Anti-retroviral treatment induced a significant reduction in virus load, with the percentage of women with fewer than 1,000 viral copies per millilitre (c/ml) rising from 17% at baseline to 90% by the time of delivery. A total of 707 children were tested at 1 month of age, and 467 were retested at 6 months. The HIV incidence rate was 3.8% (CL95% 3.1-4.5) at 1 month, with an additional 1.5% (CL95%: 0.9-2.1) of babies testing positive at 6 months. The cumulative intention-to-treat incidence rate was 5.3% at 6 months. When data for women who stayed on treatment for the full duration of the protocol were analysed separately, vertical transmission rates dropped to 1.4% at 6 months. Maternal mortality was 0.8% (eight deaths in 993 pregnancies). The incidence rate of significant hepatic, dermatological and haematological adverse reactions to anti-retroviral agents on a sub-sample of 778 pregnant women was 6.1% (CL95% 4.2-8.0), 3.2% (CL95% 2.0-3.4) and 14.1% (CL95% 11.6-16.6), respectively.
Base-line parameters, risk factors for vertical transmission, and multivariate analysis of the determinants of HIV positive status are shown in Tables 1, 2 and 3. The current data are highly relevant for the development of future programmes for the prevention of HIV MTCT in the developing world. The acceptability of HAART during pregnancy was higher than that of single-dose nevirapine in prior studies [5, 6] . Even within the Mozambique health care system, where about 50% of women deliver at home, it was still possible to get women tested for HIV early in the course of pregnancy. A surprisingly large percentage of women (86%) who tested positive enrolled, and 95% (931/ 985) of those completed the entire protocol. The public health impact on vertical transmission was much higher than previously described [1, [3] [4] [5] [6] , with a cumulative intention-to-treat (ITT) analysis transmission rate at 6 months of age of 5.3%. Among women who received HAART until 6 months postpartum, no transmissions occurred beyond 1 month of age. These results demonstrate that, in resource-limited settings, very low HIV transmission rates, equivalent to those observed in developed countries, are achievable [2] . In addition, the decision to use HAART in the postpartum period could potentially render breastfeeding safe during the first 6 months of life. 
